Upjohn Colestid Rx-to-OTC switch for cholesterol lowering pending at FDA.
Executive Summary
UPJOHN COLESTID Rx-TO-OTC SWITCH APPLICATION PENDING AT FDA and may be discussed at a joint meeting of FDA's Endocrinologic & Metabolic Drugs and Nonprescription Drugs Advisory Committees this year. Colestid (colestipol), a prescription cholesterol- lowering agent, is available in tablets and regular or orange-flavored granules that are mixed with water or other fluids. Upjohn filed the switch application in 1994.